Barentzymes

Barentzymes AS was a Northern Norwegian biotechnology company founded in December 2013 by Jan B. Andersen, a former chief executive of ArcticZymes AS, and Sigurd Aase, a private Norwegian investor. The company was headquartered in Tromsø, where it operated a wet laboratory, while its bioinformatics and business-development activities were based in Copenhagen, Denmark. Its stated organization included a Tromsø team of approximately nine employees and a Copenhagen group of approximately six people, with members recruited from research environments associated with the Technical University of Denmark and Aalborg University. The company’s business concept was to discover and commercialize novel enzymes for industrial biotechnology. Its initial focus was the biological degradation and processing of resources for both food and non-food applications. Rather than concentrating only on conventional enzyme production, Barentzymes sought to identify original enzymes associated with the genetic resources of the Barents Sea and translate them into tailored solutions for customers’ technical problems. A central part of its approach was the use of bioinformatics and the Peptide Pattern Recognition principle, or PPR, to identify promising enzyme candidates from sequence data. The company described this platform as capable of predicting important enzyme properties at the sequence level before extensive laboratory testing. That approach was intended to shorten development cycles, reduce costs, and help match enzyme candidates to specific customer applications. One reported research direction involved the discovery of new beta-glucosidases from Mucor circinelloides. Barentzymes operated within a Northern Norwegian biotechnology cluster that connected public institutions with industrial participants seeking to research and commercialize the biodiversity of the Barents Sea. Its work attracted recognition from Norway’s Ministry of Trade and Industry, which selected the company for an official visit in connection with its biotechnology activities. The company’s operations were short-lived. Its funding was stopped on short notice, and business activities ended in mid-2015. The available reference material does not document a commercial product portfolio, major customer contracts, ownership changes, or a successor organization. Barentzymes is therefore best understood as a discontinued, research-driven industrial biotechnology venture rather than an active consumer or pharmaceutical brand.

Barentzymes AS was created in December 2013 in Tromsø, Northern Norway, as a biotechnology venture centered on enzyme discovery for industrial applications. Its founders were Jan B. Andersen, who had previously served as chief executive of ArcticZymes AS, and Sigurd Aase, a private Norwegian investor. The venture was established during a period in which Northern Norwegian research and industry organizations were seeking ways to convert regional biological resources into commercial technologies. The company developed a distributed operating model. Its wet-laboratory and main headquarters activities were located in Tromsø, while bioinformatics and business development were conducted from Copenhagen, Denmark. The available account describes approximately nine employees in Tromsø and six in Copenhagen. The computational team included researchers recruited from the Center for Biological Sequence Analysis at the Technical University of Denmark and from the BioInstitute at Aalborg University’s Copenhagen campus. Barentzymes’ intended market was industrial biotechnology rather than consumer healthcare. It aimed to bring new enzymes to market for the degradation and processing of biological resources in food and non-food applications. The company’s research strategy emphasized the genetic resources of the Barents Sea and sought to identify enzymes with useful properties that could be developed for specific industrial processes. Its discovery platform combined laboratory biotechnology with bioinformatics. Barentzymes applied the Peptide Pattern Recognition principle to search for promising enzyme sequences, including beta-glucosidases associated with Mucor circinelloides. The company’s specialists had developed methods intended to predict enzyme properties directly from sequence information. By screening candidates computationally before undertaking extensive laboratory work, Barentzymes sought to reduce the time and expense required to move from discovery to application testing. The company described its commercial model as customer-oriented and collaborative. Instead of offering only a standardized catalogue, it worked toward tailored enzyme solutions designed around a customer’s particular technical requirement. This model was intended to connect original enzyme discovery with practical processing challenges in industrial biotechnology. Barentzymes was part of a Northern Norway cluster that brought together public institutions and industry representatives to research and commercialize the biodiversity of the Barents Sea. Its activities received official attention when Norway’s Ministry of Trade and Industry selected the company for a visit recognizing its biotechnology work. The venture did not continue for long. Its funding was stopped with little notice, and the company’s operations ended in mid-2015. The available sources do not establish that Barentzymes launched a durable commercial product line, completed a merger, or continued under another corporate identity. Its historical significance lies primarily in its attempt to combine Arctic-region genetic resources, computational enzyme discovery, and application-focused industrial biotechnology within a small Norwegian startup.

• 2015

  Operations discontinued

  [1]Barentzymesen.wikipedia.org

  Funding was stopped on short notice, and Barentzymes ceased operations in mid-2015.

• 2013

  Company established

  [1]Barentzymesen.wikipedia.org

  Barentzymes AS was founded in December 2013 in Tromsø by Jan B. Andersen and Sigurd Aase.

• Ministry of Trade and Industry visit

  [1]Barentzymesen.wikipedia.org

  The company was selected for an official visit by Norway’s Ministry of Trade and Industry in recognition of its biotechnology activities.

A research-led industrial biotechnology venture focused on discovering original enzymes from Barents Sea genetic resources and using bioinformatics to develop application-specific solutions for food and non-food processes.

• Industrial biotechnology

  Industrial enzyme candidates

  Barentzymes pursued new enzymes for biological degradation and processing in food and non-food industrial applications. The work focused on finding original enzyme activities associated with genetic resources from the Barents Sea and adapting candidate molecules to particular customer requirements. The available sources do not identify a launched commercial product or a completed product catalogue.

• Enzyme discovery

  Beta-glucosidase discovery

  One reported research direction involved using the company’s Peptide Pattern Recognition-based bioinformatics approach to discover new beta-glucosidases from Mucor circinelloides. The platform was intended to predict enzyme properties from sequence information and prioritize candidates for laboratory evaluation. The sources do not confirm commercialization of these candidates.

• 2015

  Operations ended following funding discontinuationStrategy

  Background

  Barentzymes was a small biotechnology venture whose business depended on continued funding for research, bioinformatics, and laboratory operations.

  Action taken

  Funding was stopped on short notice, and the company ended its operations in mid-2015.

  Aftermath

  The available material indicates that Barentzymes became defunct. It does not provide details about creditors, liquidation proceedings, assets, or successor organizations.

  Source

1. 1Barentzymesen.wikipedia.org